Overview Dividends

(BIIB) Biogen - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09062X1037

Multiple Sclerosis Therapies, Spinal Muscular Atrophy Treatment, Biosimilars, Neurodegenerative Disease Drugs, Anti-CD20 Agents

BIIB EPS (Earnings per Share)

EPS Growth (3Y CAGR): 6.45%
EPS Trend (3Y Correlation): 26.7%

BIIB Revenue

Revenue Growth (3Y CAGR): -1.29%
Revenue Trend (3Y Correlation): 7.2%

Risk via 10d forecast
Volatility	32.8%
Value at Risk 5%th	52.6%
Relative Tail Risk	-2.66%

Reward TTM
Sharpe Ratio	0.06
Alpha	-10.24

Character TTM
Hurst Exponent	0.419
Beta	0.576
Beta Downside	0.509

Drawdowns 3y
Max DD	64.35%
Mean DD	33.06%
Median DD	30.93%

Description: BIIB Biogen October 16, 2025

Biogen Inc. (NASDAQ: BIIB) discovers, develops, manufactures, and markets therapies for neurological and neurodegenerative diseases across the United States, Europe, Germany, Asia, and other international markets. Its approved portfolio includes multiple-sclerosis drugs (Tecfidera, Vumerity, Avonex, Plegridy, Tysabri, Ocrevus), spinal muscular atrophy treatment (Spinraza), Friedreich’s ataxia (Skyclarys), ALS (Qalsody), plaque-psoriasis (Fumaderm), and a suite of biosimilars (Benepali, Imraldi, Flixabi, Byooviz, Tofidence). The company also sells oncology and autoimmune agents such as Rituxan, Rituxan Hycela, Gazyva, Lunsumio, and glofitamab, while advancing pipelines in MS, Alzheimer’s, Parkinson’s, neuropsychiatry, and additional biosimilars through collaborations with partners like Merz, Alkermes, Denali, Eisai, Genentech, Ionis, and Sage.

Key recent metrics: Biogen reported FY 2024 revenue of $10.5 billion, with MS therapies contributing roughly 45 % of total sales, while biosimilar launches added an estimated $350 million in Q3 2024. The global MS drug market is projected to grow at a 6 % CAGR through 2030, driven by an aging population and expanding diagnostic rates, positioning Biogen’s Ocrevus and upcoming generics for market share gains. Additionally, biotech R&D intensity remains above 20 % of revenues industry-wide, underscoring the importance of Biogen’s partnership pipeline (e.g., Denali’s antisense programs) for sustaining long-term growth.

For a deeper, data-driven assessment of Biogen’s valuation and risk profile, you may find the analytical tools on ValueRay worth exploring.

BIIB Stock Overview

Market Cap in USD	24,580m
Sub-Industry	Biotechnology
IPO / Inception	1991-09-16
Return 12m vs S&P 500	-8.26%
Analyst Rating	3.81 of 5

BIIB Dividends

Currently no dividends paid

BIIB Growth Ratios

CAGR 3y	-18.06%
CAGR/Max DD Calmar Ratio	-0.28
CAGR/Mean DD Pain Ratio	-0.55
Current Volume	2620.4k
Average Volume	1659.7k

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (1.61b TTM) > 0 and > 6% of Revenue (6% = 599.2m TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA 1.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 56.55% (prev 14.63%; Δ 41.92pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 2.45b > Net Income 1.61b (YES >=105%, WARN >=100%)

Net Debt (2.73b) to EBITDA (3.49b) ratio: 0.78 <= 3.0 (WARN <= 3.5)

Current Ratio 2.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (147.1m) change vs 12m ago 0.82% (target <= -2.0% for YES)

Gross Margin 70.12% (prev 71.78%; Δ -1.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 34.72% (prev 33.93%; Δ 0.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 10.50 (EBITDA TTM 3.49b / Interest Expense TTM 260.0m) >= 6 (WARN >= 3)

Altman Z'' 6.15

(A) 0.19 = (Total Current Assets 8.94b - Total Current Liabilities 3.29b) / Total Assets 29.21b

(B) 0.71 = Retained Earnings (Balance) 20.60b / Total Assets 29.21b

(D) 1.85 = Book Value of Equity 20.39b / Total Liabilities 11.00b

Total Rating: 6.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 71.83

1. Piotroski 6.0pt = 1.0

2. FCF Yield 8.37% = 4.18

3. FCF Margin 22.81% = 5.70

4. Debt/Equity 0.36 = 2.44

5. Debt/Ebitda 0.78 = 2.04

6. ROIC - WACC (= 3.05)% = 3.82

7. RoE 9.25% = 0.77

8. Rev. Trend 7.20% = 0.54

9. EPS Trend 26.69% = 1.33

What is the price of BIIB shares?

As of November 17, 2025, the stock is trading at USD 167.55 with a total of 2,620,400 shares traded.
Over the past week, the price has changed by +7.23%, over one month by +17.78%, over three months by +23.28% and over the past year by +6.08%.

Is Biogen a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Biogen (NASDAQ:BIIB) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 71.83 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BIIB is around 151.37 USD . This means that BIIB is currently overvalued and has a potential downside of -9.66%.

Is BIIB a buy, sell or hold?

Biogen has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy BIIB.

Strong Buy: 13
Buy: 4
Hold: 20
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BIIB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	176.1	5.1%
Analysts Target Price	176.1	5.1%
ValueRay Target Price	165.9	-1%

BIIB Fundamental Data Overview November 17, 2025

Market Cap USD = 24.58b (24.58b USD * 1.0 USD.USD)
P/E Trailing = 15.2735
P/E Forward = 10.7181
P/S = 2.4419
P/B = 1.35
P/EG = 6.2424
Beta = 0.145
Revenue TTM = 9.99b USD
EBIT TTM = 2.73b USD
EBITDA TTM = 3.49b USD
Long Term Debt = 6.29b USD (from longTermDebt, last quarter)
Short Term Debt = 1.75b USD (from shortTermDebt, last fiscal year)
Debt = 6.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.73b USD (from netDebt column, last quarter)
Enterprise Value = 27.21b USD (24.58b + Debt 6.59b - CCE 3.96b)
Interest Coverage Ratio = 10.50 (Ebit TTM 2.73b / Interest Expense TTM 260.0m)
FCF Yield = 8.37% (FCF TTM 2.28b / Enterprise Value 27.21b)
FCF Margin = 22.81% (FCF TTM 2.28b / Revenue TTM 9.99b)
Net Margin = 16.11% (Net Income TTM 1.61b / Revenue TTM 9.99b)
Gross Margin = 70.12% ((Revenue TTM 9.99b - Cost of Revenue TTM 2.98b) / Revenue TTM)
Gross Margin QoQ = 64.29% (prev 64.23%)
Tobins Q-Ratio = 0.93 (Enterprise Value 27.21b / Total Assets 29.21b)
Interest Expense / Debt = 1.02% (Interest Expense 67.4m / Debt 6.59b)
Taxrate = 16.29% (90.8m / 557.3m)
NOPAT = 2.29b (EBIT 2.73b * (1 - 16.29%))
Current Ratio = 2.72 (Total Current Assets 8.94b / Total Current Liabilities 3.29b)
Debt / Equity = 0.36 (Debt 6.59b / totalStockholderEquity, last quarter 18.21b)
Debt / EBITDA = 0.78 (Net Debt 2.73b / EBITDA 3.49b)
Debt / FCF = 1.20 (Net Debt 2.73b / FCF TTM 2.28b)
Total Stockholder Equity = 17.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.51% (Net Income 1.61b / Total Assets 29.21b)
RoE = 9.25% (Net Income TTM 1.61b / Total Stockholder Equity 17.38b)
RoCE = 11.53% (EBIT 2.73b / Capital Employed (Equity 17.38b + L.T.Debt 6.29b))
RoIC = 9.65% (NOPAT 2.29b / Invested Capital 23.67b)
WACC = 6.60% (E(24.58b)/V(31.17b) * Re(8.14%) + D(6.59b)/V(31.17b) * Rd(1.02%) * (1-Tc(0.16)))
Discount Rate = 8.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.48%
[DCF Debug] Terminal Value 79.89% ; FCFE base≈2.07b ; Y1≈2.39b ; Y5≈3.35b
Fair Price DCF = 387.4 (DCF Value 56.83b / Shares Outstanding 146.7m; 5y FCF grow 17.62% → 3.0% )
EPS Correlation: 26.69 | EPS CAGR: 6.45% | SUE: 1.64 | # QB: 2
Revenue Correlation: 7.20 | Revenue CAGR: -1.29% | SUE: 0.86 | # QB: 3

Additional Sources for BIIB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle